Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: NOVARTIS FARMA
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A study to evaluate the effects of fingolimod teatment in patients with acute demyelinating optic neuritis
To assess if fingolimod will reduce the mean retinal nerve fiber layer (RNFL) thinning (measured as the OCT-determined difference between the RNFLT of the affected eye after 18 weeks of treatment and ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Once-a-day regimen or Steroid withdrawal in de novo kidney transplant recipients treated with everolimus, cyclosporin and steroids: a 12-month, prospective, randomized, multicenter, open-label study. The EVIDENCE study (EVerol/mus once-a-Day rEgimen with Neoral versus Corticosteroid Elimination)
The primary objective of the study is to demonstrate, in renal transplant patients receiving everolimus and cyclosporin, the non-inferiority of one of the two following regimens: once-a-day regimen (G...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg administered once daily in patients with Amyotrophic Lateral Sclerosis
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type Psoriasis Sicurezza ed efficacia di Secukinumab in confronto a Etarnecerpt in soggetti con psoriasi cronica a placche da moderata a severa
Efficacy of secukinumab compared to placebo in subjects with moderate to severe chronic plaque-type psoriasis over 12 weeks based on PASI and IGA Dimostrare la superiorità di secukinumab rispe...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patients with Type 2 Diabetes treated with differing baseline diabetes therapies
The primary objective is to evaluate canakinumab effects on change from baseline of meal challenge derived insulin secretion rate relative to glucose 0-2 hours (Φd), at 4 weeks, on the following...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A Phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma Studio di Fase II con BKM120 in pazienti con linfoma B diffuso a grandi cellule, linfoma mantellare e linfoma follicolare, recidivanti e refrattari
To determine the efficacy of BKM120 in patients with relapsed/refractory Non-Hodgkin Lymphoma in the three different histological subgroups (cohorts) Determinare l’efficacia di BKM120 in pazien...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib
To evaluate the preliminary efficacy of nilotinib in pretreated patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as stable disease (SD), partial response (...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A study to provide expanded access of Exjade deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelators
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CCOX189A0112, CCOX189A0109 or CCOX189A2361
The primary objective of this post-hoc pharmacogenetic sub-study is to determine whether patients who experienced severe hepatotoxicity when taking lumiracoxib are carriers of the DQA1*0102 allele.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monotherapy, and with telbivudine monotherapy in treatment na ve patients with HBeAg-positive compensated CHB
The primary objective of this study is to demonstrate the superior antiviral efficacy of the combination of peginterferon alpha-2a plus telbivudine vs. peginterferon alpha-2a monotherapy as demonstrat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
Next